# Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

> **NCT03466216** · PHASE1 · TERMINATED · sponsor: **Orano Med LLC** · enrollment: 33 (actual)

## Conditions studied

- Neuroendocrine Tumor

## Interventions

- **DRUG:** AlphaMedix

## Key facts

- **NCT ID:** NCT03466216
- **Lead sponsor:** Orano Med LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-05
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-04-06
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Terminated for non-safety reasons.
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466216, "Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03466216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*